As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Hosted on MSN4h
2 Dividend Stocks to Buy Hand Over Fist in NovemberDividend investors can safely add this stock to their portfolios this month. It hasn't been smooth sailing for Amgen in ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.
Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...
Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...
Amgen's acquisition of Horizon Therapeutics has notably contributed to its revenue stream, with Horizon products adding $1.1 billion in sales for the quarter. Despite macroeconomic headwinds ...
“Amgen Inc. (NASDAQ:AMGN) is a large cap global biotech company with a diverse portfolio of marketed and pipeline products. Amgen’s discovery pipeline had led the company to broaden its focus ...
Discover how Amgen is achieving a fully automated enterprise through strategic partnerships with Cognizant and UiPath to enhance efficiency.
A potential competitor to Lilly’s Zepbound may be in some trouble. Amgen’s weight loss drug was found to negatively impact bone density in early trials. Shares of Amgen fell as a result. While ...
THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback